| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $14.4M | -16.0% |
| SG&A Expense | $10.2M | -13.1% |
| Operating Income | -$24.6M | +14.8% |
| Pre-tax Income | -$24.1M | -29.4% |
| Net Income | -$24.1M | -38.6% |
| EPS (Basic) | -$87.38 | -6053.5% |
| EPS (Diluted) | -$87.38 | -6053.5% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $8.7M | -48.5% |
| Current Assets | $10.7M | -44.1% |
| Total Assets | $15.6M | -37.2% |
| Current Liabilities | $6.2M | -14.1% |
| Total Liabilities | $10.8M | -14.1% |
| Stockholders' Equity | $4.8M | -61.1% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$23.8M | -102.8% |
| Investing Cash Flow | $0 | — |
| Financing Cash Flow | $15.6M | +160.0% |